IMMUNORX PHARMA

immunorx-pharma-logo

ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and Crohnโ€™s disease. The company's antibody targets a new critical target in chronic inflammation and auto-immunity which was originally discovered by Dr. Tessier in Canada.

#SimilarOrganizations #People #More

IMMUNORX PHARMA

Industry:
Health Care Medical Medical Device

Founded:
2020-01-01

Status:
Active

Total Funding:
2.67 M USD


Similar Organizations

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

equinox-logo

Equinox

Equinox is a developer of a medical technology in revolutionizing the treatment of glaucoma and other progressive eye diseases.

intouch-health-logo

InTouch Health

InTouch Health is the leader in Acute Care Telemedicine solutions.

pandion-therapeutics-logo

Pandion Therapeutics

Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.

portal-instruments-logo

Portal Instruments

Portal Instruments is an early stage company that offers medical device.

summit-bhc-logo

Summit BHC

Summit Behavioral Healthcare is an Atlanta-based provider of addiction treatment and behavioral health services.

tiburio-therapeutics-logo

Tiburio Therapeutics

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.

Current Employees Featured

caroline-fortier_image

Caroline Fortier
Caroline Fortier CEO @ ImmunoRx Pharma
CEO
2020-11-01

More informations about "ImmunoRx Pharma"

ImmunoRx Pharma - Crunchbase Company Profile

ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and โ€ฆSee details»

ImmunoRx Pharma - Funding, Financials, Valuation & Investors

ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases.See details»

ImmunoRx Pharma 2025 Company Profile: Valuation, โ€ฆ

Information on valuation, funding, cap tables, investors, and executives for ImmunoRx Pharma. Use the PitchBook Platform to explore the full profile.See details»

TVM Life Science Innovation II SCSp Announces Investment in โ€ฆ

Jan 19, 2021 ImmunoRx Pharma, Inc. plans to begin clinical development by the end of 2022. Once cleared for clinical development by regulatory authorities, the ImmunoRx Pharma, Inc. โ€ฆSee details»

ImmunoRx Pharma Inc. - TVM Capital Life Science โ€ฆ

ImmunoRx Pharma, Inc. plans to develop a first-in-class antibody, to proof-of-concept, with the potential to treat certain types of chronic inflammatory diseases, including ulcerative colitis, rheumatoid arthritis and Crohnโ€™s disease. This โ€ฆSee details»

Immunorx Pharma, Inc. Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Immunorx Pharma, Inc. of Wilmington, DE. Get the latest business insights from Dun & Bradstreet.See details»

ImmunoRx - LinkedIn

ImmunoRx | 335 followers on LinkedIn. A subsidiary of Voirx, Focuses on manufacturing cancer oncolytics and immunotherapeutic productsSee details»

Immunorx Pharma, Inc. | MedPath

First Posted Date 2024-04-10 Last Posted Date 2025-03-26 Lead Sponsor ImmunoRx Pharma Inc. Target Recruit Count 83 Registration Number NCT06356259See details»

ImmunoRx Pharma, Inc. - Drug pipelines, Patents, Clinical trials

Explore ImmunoRx Pharma, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 2 news, Technology Platform:Biological products, Drug ...See details»

IMMUNORX PHARMA, INC. Top 13F Holdings - WhaleWisdom.com

Detailed Profile of IMMUNORX PHARMA, INC. portfolio of holdings. SEC Filings include 13F quarterly reports, 13D/G events and more.See details»

IRX-010 by ImmunoRx Pharma for Inflammation: Likelihood of โ€ฆ

Jan 6, 2025 IRX-010 is under clinical development by ImmunoRx Pharma and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase โ€ฆSee details»

ImmunoRx Pharma - Contacts, Employees, Board Members

ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases.See details»

ImmunoRx Pharma | VentureRadar

RDP Pharma (RDP) is a privately held biotech, dedicated to the vision that their products will deliver valuable medicines to patients in need. The company's projects include: Next โ€ฆSee details»

ImmunoRx Pharma - Products, Competitors, Financials, Employees ...

About ImmunoRx Pharma ImmunoRx Pharma develops the first-in-class antibody, to proof-of-concept, with the potential to treat certain types of chronic inflammatory diseases, including โ€ฆSee details»

IRX-010 - Drug Targets, Indications, Patents - Synapse

Mar 28, 2025 IRX-010, Initially developed by ImmunoRx Pharma, Inc., Now, its global highest R&D status is Discontinued.See details»

TVM Capital Life Science acquires ImmunoRx Pharma - Crunchbase

Jan 19, 2021 ImmunoRx Pharma ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases.See details»

ImmunoRx Pharma, Inc.: Drug pipelines, Patents, Clinical trials

Explore ImmunoRx Pharma, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»

IRX 010 - AdisInsight

Apr 23, 2024 IRX 010 is intravenous drug candidate being developed by ImmunoRx Pharma for undisclosed indication. Clinical development is underway in Netherlands.See details»

ImmunoRx Pharma - VentureRadar

The venture focuses on accurately replicating biological processes to simulate clinical trial outcomes without the need for a client to step into a lab. The venture has two validated โ€ฆSee details»

ImmunoRx Pharma - Updates, News, Events, Signals & Triggers

Jan 19, 2021 ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases.See details»

linkstock.net © 2022. All rights reserved